Clinical trial · Observational
Nutritional Status in Neuroblastoma in Sao Paolo, Brazil
The Role of Nutritional Status in the Treatment of Neuroblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study proposes to investigate the effect of treatment of neuroblastoma on nutritional status, assessed by body mass index (BMI) z score, and body composition evaluated by mid-upper arm circumference (MUAC), from diagnosis through 1-year post end of treatment. The study also aims to investigate the nutritional status and its role in toxicities, infection, survival rates, disease relapse, cost of care and readmission rates, as well as health-related quality of life. The study will take place in Sao Paolo in Brazil, where an estimated sample of 50 children with neuroblastoma will be recruited for the period of 2 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Children with Neuroblastoma
- description
- Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
Primary outcomes (3)
- measure
- Body Mass Index Z Score
- timeFrame
- Up to 1 year post treatment
- description
- Effect of neuroblastoma treatment in nutritional status: Nutritional status will be measured by BMI Z score
- measure
- Mid-upper arm circumference (MUAC)
- timeFrame
- Up to 1 year post treatment
- description
- Effect of neuroblastoma treatment in body composition: Body composition will be measured by mid-upper arm circumference (MUAC)
- measure
- Measurement from Bioelectrical Impedance Analysis (BIA)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of high-risk neuroblastoma at ITACI, according to the Pediatric Oncology Group (POG)/Children's Cancer Study Group (CCG) classification (International Neuroblastoma Staging System (INSS) stage) * Age under 18 years * Informed consent from a legal guardian to participate in the study Exclusion Criteria: * Patients who have received previous chemotherapy * First assessment performed more than 48 hours after the beginning of treatment
References
Publications (0)
Data not yet available